| Number of patients (%) | 2716 | 453 (16.7) | 741 (27.3) | 1522 (56) |
| Female sex (%) | 2176 (80.1) | 325 (71.7) | 599 (80.8) | 1252 (82.3) |
| Age at treatment start (years); mean (SD) | 59.3 (13.3) | 61.7 (14.0) | 60.7 (12.9) | 57.8 (13.0) |
| Duration of RA at treatment start (years); mean (SD) | 14.2 (11.4) | 9.5 (11.1) | 14.4 (11.8) | 15.5 (10.8) |
| Intravenous treatment | 1365 (50.3%) | 194 (42.8%) | 381 (51.8%) | 790 (52.1%) |
| Subcutaneous treatment | 1338 (49.3%) | 257 (57.0%) | 355 (48.2%) | 726 (47.9%) |
| ESR (mm 1st h); median (IQR) | 23 (11–42) | 23 (12–42) | 23.5 (12–40.25) | 22 (10–41) |
| CRP (mg/l); median (IQR) | 9 (3.5–23) | 11 (5–24) | 8 (3.48–23) | 8 (3–22) |
| DAS28; mean (SD) | 4.98 (1.29) | 5.01 (1.23) | 4.93 (1.28) | 4.99 (1.31) |
| DAS28-CRP; mean (SD) | 4.66 (1.13) | 4.64 (1.14) | 4.57 (1.13) | 4.70 (1.13) |
| VAS pain (0–100); mean (SD) | 60 (23) | 58 (24) | 59 (23) | 62 (22) |
| VAS global (0–100); mean (SD) | 60 (22) | 56 (23) | 60 (23) | 62 (22) |
| Swollen joint count (0–28); median (IQR) | 5 (2–9) | 6 (3–10) | 5 (2–8) | 5 (2–9) |
| Tender joint count (0–28); median (IQR) | 6 (3–10) | 6 (2–11) | 6 (3–10) | 6 (3–11) |
| HAQ-DI (0–3); mean (SD) | 1.32 (0.63) | 1.16 (0.63) | 1.30 (0.65) | 1.37 (0.62) |
| Physicians global (0–4); median (IQR) | 2 (2–3) | 2 (2–3) | 2 (2–3) | 2 (2–3) |
| Current methotrexate | 1288 (57%) | 196 (55%) | 373 (61%) | 719 (55%) |
| Current glucocorticoids | 1316 (49%) | 176 (39%) | 345 (47%) | 795 (52%) |
| Glucocorticoids dose in mg, prednisolone equivalent; mean (SD) | 7.5 (4.2) | 7.6 (3.9) | 6.9 (4.0) | 7.8 (4.3) |
| Current csDMARD | 1489 (55%) | 237 (52%) | 425 (57%) | 827 (54%) |
